Cubarmix Equi 400 mg/g and 80 mg/g oral powder for horses
Cubarmix Equi 400 mg/g and 80 mg/g oral powder for horses
Authorised
- Sulfadiazine
- Trimethoprim
Product identification
Medicine name:
Cubarmix Equi 400 mg/g and 80 mg/g oral powder for horses
TRISULMIX EQUI 400 MG/G + 80 MG/G POUDRE ORALE POUR CHEVAUX
Active substance:
- Sulfadiazine
- Trimethoprim
Target species:
-
Horse
Route of administration:
-
Oral use
Product details
Active substance and strength:
-
Sulfadiazine400.00/milligram(s)1.00gram(s)
-
Trimethoprim80.00/milligram(s)1.00gram(s)
Pharmaceutical form:
-
Oral powder
Withdrawal period by route of administration:
-
Oral use
-
Horse
-
Meat and offal6month
-
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QJ01EW10
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
France
Package description:
- White cylindrical polypropylene container, covered with a low density polyethylene lid containing 500g of oral powder.
- White cylindrical polypropylene container, covered with a low density polyethylene lid containing 800g of oral powder.
- Heat-sealed, white coloured, 4-layer sachet containing 12.5 g of oral powder. 15 sachets per pack.
- Heat-sealed, white coloured, 4-layer sachet containing 12.5 g of oral powder. 100 sachets per pack
- Heat-sealed, white coloured, 4-layer sachet containing 37.5 g of oral powder. 5 sachets per pack
- Heat-sealed, white coloured, 4-layer sachet containing 37.5 g of oral powder. 10 sachets per pack
- Heat-sealed, white coloured, 4-layer sachet containing 37.5 g of oral powder. 100 sachets per pack
- Heat-sealed, white coloured, 4-layer sachet containing 50 g of oral powder. 5 sachets per pack
- Heat-sealed, white coloured, 4-layer sachet containing 50 g of oral powder. 10 sachets per pack
- Heat-sealed, white coloured, 4-layer sachet containing 50 g of oral powder. 100 sachets per pack
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Hybrid application – change in strength (Article 19(1)(a) of Regulation (EU) 2019/6)
Marketing authorisation holder:
- Dopharma Research B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
- Dopharma B.V.
- Dopharma France
Responsible authority:
- French Agency For Food, Environmental And Occupational Health & Safety
Authorisation number:
- FR/V/7314102 8/2026
Date of authorisation status change:
Reference member state:
-
Ireland
Procedure number:
- IE/V/0673/001
Concerned member states:
-
Austria
-
Belgium
-
Denmark
-
France
-
Germany
-
Hungary
-
Italy
-
Netherlands
-
Poland
-
Romania
-
Spain
-
Sweden
-
United Kingdom (Northern Ireland)
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it
in another language below.
French (PDF)
Published on: 10/02/2026
Package Leaflet and Labelling
This document does not exist in this language (English). You can find it
in another language below.
French (PDF)
Published on: 10/02/2026